Weifang Ruze New Material Co., Ltd.

 

Your Aspiration is Our Commitment

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsAntineoplastic Drugs

White Powder Inhibitor Sparsentan RE-021 For Treatment FSGS CAS 254740-64-2

Ruze supply good service, thanks.

—— Gaurav

I'm Online Chat Now

White Powder Inhibitor Sparsentan RE-021 For Treatment FSGS CAS 254740-64-2

China White Powder Inhibitor Sparsentan RE-021 For Treatment FSGS CAS 254740-64-2 supplier
White Powder Inhibitor Sparsentan RE-021 For Treatment FSGS CAS 254740-64-2 supplier White Powder Inhibitor Sparsentan RE-021 For Treatment FSGS CAS 254740-64-2 supplier

Large Image :  White Powder Inhibitor Sparsentan RE-021 For Treatment FSGS CAS 254740-64-2

Product Details:

Place of Origin: Weifang,China
Brand Name: Ruze
Certification: COA MSDS
Model Number: 254740-64-2

Payment & Shipping Terms:

Minimum Order Quantity: Negotiable
Price: Negotiable
Packaging Details: 1kg/drum
Delivery Time: 5-7 work days
Payment Terms: L/C, T/T, Western Union, MoneyGram
Supply Ability: 1000kg/week
Contact Now
Detailed Product Description
CAS: 254740-64-2 MF: C32H40N4O5S
MW: 592.7488 Boiling Point: 744.4±70.0 °C(Predicted)
Density: 1.28±0.1 G/cm3(Predicted) Acidity Coefficient (pKa): 7.06±0.50(Predicted)
Color: White Color Powder

 

Advantage of our API-CAS 254740-64-2

 

1. High purity

2. Consistent quality for Lorlatinib

3. Competitive price

4. Fast Shipping for Lorlatinib

 

White Powder Inhibitor Sparsentan RE-021 For Treatment FSGS CAS 254740-64-2

 

Name
Sparsentan
Accession Number
DB12548 (DB05206)
Type
Small Molecule
Groups
Investigational
Description

Sparsentan has been used in trials studying the treatment of Focal Segmental Glomerulosclerosis. Sparsentan is the first and only dual-acting angiotensin and endothelin receptor antagonist (DARA) in development.





 
 
 
Synonyms
Not Available
External IDs
PS-433540 / PS433540 / RE-021
Categories
Not Available

CAS number
254740-64-2
Weight
Average: 592.76
Monoisotopic: 592.271941578
Chemical Formula
C32H40N4O5S
InChI Key
WRFHGDPIDHPWIQ-UHFFFAOYSA-N
InChI
InChI=1S/C32H40N4O5S/c1-5-7-14-29-33-32(17-10-11-18-32)31(37)36(29)20-24-15-16-26(25(19-24)21-40-6-2)27-12-8-9-13-28(27)42(38,39)35-30-22(3)23(4)41-34-30/h8-9,12-13,15-16,19H,5-7,10-11,14,17-18,20-21H2,1-4H3,(H,34,35)
IUPAC Name
4'-({2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl}methyl)-N-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
SMILES
CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C(COCC)=C1)C1=CC=CC=C1S(=O)(=O)NC1=NOC(C)=C1C
 
 
Mechanism of action

Sparsentan, which possesses two clinically validated mechanisms of action in a single molecule, works by selectively blocking the action of two potent vasoconstrictor and mitogenic agents, angiotensin II (AII) and endothelin 1 (ET1), at their respective receptors. Sparsentan is highly selective (10,000-fold) for the AII receptor sub-type 1 and the ET receptor sub-type A. As such, Sparsentan combines the properties of an angiotensin receptor blocker (ARB) and an endothelin receptor antagonist (ERA) in the same molecule.

 

Focal segmental glomerulosclerosis (FSGS) is a common glomerular disease, and patients often show varying degrees of proteinuria and nephrotic syndrome. Its incidence is increasing, and approximately 50% of patients with primary FSGS and nephropathy-range proteinuria in the United States require RRT for 5-10 years after diagnosis. FSGS has a poor prognosis and is a common cause of end-stage renal disease (ESRD) in adults (5%) and children (12%).

Currently the main treatments are corticosteroids and other immunosuppressants, which are designed to reduce proteinuria, an independent predictor of kidney survival in patients with primary FSGS. These drugs are usually used in combination with renin-angiotensin system inhibitors (RASIs), but side effects caused by immunosuppressants often limit their clinical application. Therefore, there is an urgent need for drugs that can effectively and safely relieve FSGS proteinuria and are well tolerated.

Studies have shown that endothelin (ET) and angiotensin II can damage podocytes through various molecular mechanisms, and endothelin receptor antagonists (ERAs) and RASIs can improve parenchymal damage and reduce proteinuria.

Sparsentan is a drug that blocks both the angiotensin II and endothelin 1 receptors. To determine its effectiveness and safety in the treatment of FSGS, the Howard Trachtman research team from New York University conducted a double-blind, randomized controlled trial . The findings are published in the JASN journal.

 

 

White Powder Inhibitor Sparsentan RE-021 For Treatment FSGS CAS 254740-64-2White Powder Inhibitor Sparsentan RE-021 For Treatment FSGS CAS 254740-64-2

White Powder Inhibitor Sparsentan RE-021 For Treatment FSGS CAS 254740-64-2White Powder Inhibitor Sparsentan RE-021 For Treatment FSGS CAS 254740-64-2White Powder Inhibitor Sparsentan RE-021 For Treatment FSGS CAS 254740-64-2

 

White Powder Inhibitor Sparsentan RE-021 For Treatment FSGS CAS 254740-64-2

 

 

We have complete experimental facilities. And advanced testing instruments ensure the stability of product quality from all aspects. We have a complete sales service system, the products are exported to countries all over the world, and have won a good international reputation with excellent quality and excellent service.Our business is based on honesty and mutual trust. Sincerely look forward to establishing long-term mutually beneficial and good cooperation with customers all over the world.

 

 

Packaging Detail

0.5kgs/Al-Bottle

1.0kgs/Al- Bottle

2.0kgs/Al- Bottle

5.0 kgs/Al-Bottle

25.0 kgs/drum

or upon customers' request.

Storage Store in a well-closed container away from moisture
Shelf Life 2 years if sealed and store away from direct sun light.
Delivery Detail within 3 days after get the payment

Contact Details
Weifang Ruze New Material Co., Ltd.

Contact Person: Ma

Tel: 86-13583611556

Send your inquiry directly to us (0 / 3000)